DYN today
$17.99+$0.07 (+0.39%)close Nov 11, 2026Trend
DailyUptrend (starting)
4 hourStrong Bullish
1 hourSymmetric Triangle
15 minStrong Bearish
5 minSymmetric Triangle
Daily trend turns down below $14.13
Key levels
Resistance$21.71
Resistance$19.39
Support$17.59
Support$16.34
Latest news & SEC filings
EarningsDyne Therapeutics Posts Q3 2026 Financials
EarningsDyne Therapeutics posts wider quarterly loss than analysts expected
SEC FilingDyne Therapeutics, Inc. filed a report on a major company event (Form 8-K)
All DYN news →About Dyne Therapeutics
Dyne Therapeutics is a clinical-stage biopharmaceutical company working on treatments for inherited muscle and nerve disorders. Its FORCE platform uses an antibody fragment that binds the transferrin receptor to carry therapeutic payloads into skeletal, heart and smooth muscle as well as the brain and spinal cord. Its pipeline targets several rare genetic conditions, including a form of muscular dystrophy, a type of myotonic disorder, facioscapulohumeral dystrophy and Pompe disease, with lead programs in early- and mid-stage clinical testing.
Based on the company's 10-K filed Mar 2, 2026.
Nasdaq · Healthcare
Dyne Therapeutics, Inc. (DYN)
What Is the Price Target for DYN?
SEPT Low Target
$15.00
SEPT Mid Target
$31.00
SEPT High Target
$47.00
Analyst Consensus
$31.00
Is DYN a Buy or Sell Right Now?
Thesis
- •SEC filings signal active product innovation — 1 new product/expansion keywords detected in 10-K. R&D investment rising.
AI-Powered Trading Signals
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy for DYN.
Start Free Trial →Is DYN Overvalued or Undervalued?
Valuation Verdict
UNDERVALUED
Methods Used
Analyst Consensus
Fair Value
$31.00
12
Moat Score
NONE
3/9
Piotroski Score
N/A
Altman Z-Score
What Is Smart Money Doing with DYN?
Insider Signal
NEUTRAL
5 buys / 14 sells (90d)
Congress Signal
NEUTRAL
0 buys / 0 sells (90d)
Institutional
N/A
Short Squeeze Risk
HIGH
Signal: HIGH_SHORT_INTEREST
Recent Insider Activity
| Name | Title | Type | Shares | Value | Date |
|---|---|---|---|---|---|
| Kerr Douglas | officer | Buy | 8,000 | - | Oct 20, 2026 |
| Posner Brian S | director | Buy | 2,500 | $40K | Oct 2, 2026 |
| Kerr Douglas | officer | Sale | 1,290 | $24K | Sep 8, 2026 |
| Cox John | director officer | Sale | 5,658 | $107K | Sep 8, 2026 |
| Friedl-Naderer Johanna | officer | Sale | 185 | $3K | Sep 8, 2026 |
| Kerr Douglas | officer | Sale | 3,745 | $91K | Sep 4, 2026 |
| Friedl-Naderer Johanna | officer | Sale | 900 | $22K | Sep 4, 2026 |
| Posner Brian S | director | Buy | 2,000 | $34K | Jun 8, 2026 |
| Posner Brian S | director | Buy | 2,500 | $44K | Jun 3, 2026 |
| Posner Brian S | director | Buy | 2,000 | $36K | May 26, 2026 |
Track Smart Money Across 4,000+ Stocks
Insider trades, congress trades, institutional flows, and short interest — updated daily with real-time alerts.
See All Smart Money Signals →DYN Growth Story
Revenue YoY
N/A%
3yr Revenue CAGR
N/A%
EPS Growth YoY
-2.97%
FCF Growth YoY
-37.5%
Revenue Trend
UNKNOWN
Dark Pool Trades for DYN
PREVIEWSEPT Investing tracks real-time dark pool institutional trades for DYN, including block trade sizes, dollar values, and buy/sell side classification. Dark pool trades reveal where institutional investors are positioning before moves become visible on public exchanges.
| Time | Price | Size | Value | Side |
|---|---|---|---|---|
| 21:00:42 | $17.99 | 1,762 | $$32K | BUY |
| 21:00:42 | $17.99 | 2,115 | $$38K | BUY |
| 21:00:41 | $17.99 | 1,016 | $$18K | BUY |
| 21:00:41 | $17.99 | 6,505 | $$117K | BUY |
| 21:00:41 | $17.99 | 2,400 | $$43K | BUY |
5 dark pool trades shown · $$248K preview volume
Real-time institutional flow, block trades, and net positioning
What Traders Are Saying About DYN
1 postsSEPT Investing hosts an active community of 3,500+ traders sharing real-time analysis, trade setups, and market discussion for DYN. Join verified traders discussing price action, dark pool alerts, options flow, and AI-powered market intelligence.
Smart Money Moves $INBX — FORSYTH DOUGLAS | Sale $287K $LDI — LEPORE DAWN G | Sale $LDI — LEPORE DAWN G | Sale $DYN — Kerr Douglas | Sale $24K $DYN — Cox John | Sale $107K
Join 3,500+ traders discussing DYN in real-time
Trade ideas, setups, dark pool alerts, and AI-powered analysis
Full AI Research Report
SEPT's Trading AI has generated a free, downloadable PDF research report for Dyne Therapeutics, Inc. (DYN) covering valuation analysis, financial health assessment, growth projections, smart money tracking, earnings and key price levels. For research only, not investment advice.
Report includes: PDF download, detailed valuation models (DCF, P/E, EV/EBITDA), institutional flow analysis, congress and insider trade tracking, FinBERT news sentiment (3 articles analyzed), and SEC filing intelligence...
AI-Powered Trading Signals.
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy. SEPT tells you when to buy, when to sell, and grades every stock so you never trade blind.
Try SEPT Free for 7 Days →DYN — frequently asked questions
What is DYN stock price today?
Dyne Therapeutics, Inc. (DYN) is at $17.99, up 0.39% (+$0.07) at the Nov 11, 2026 close.
Why is DYN stock moving today?
Latest DYN news — Nov 5, 2026: Dyne Therapeutics Posts Q3 2026 Financials · Nov 5, 2026: Dyne Therapeutics posts wider quarterly loss than analysts expected
Why did DYN stock move on Oct 28, 2026?
Dyne Therapeutics shares closed at $16.98, up 4.17% on the day, despite two bearish headlines noting that Oppenheimer cut the stock to Perform with a $15 price target. The downgrade, which changes how the firm views the shares, did not prevent the stock from rallying, as it traded between a low of $16.11 and a high of $17.11 on volume of 1,993,406.
What is the DYN price target?
The average analyst price target for DYN is $31.00, ranging from $15 to $47, based on 8 analysts. Latest: Oppenheimer downgrade on Oct 28, 2026.
What do analysts rate DYN?
Analyst ratings for DYN: 15 Buy, 1 Hold, 1 Sell — consensus Strong Buy.
Did DYN beat earnings?
DYN last reported on Nov 5, 2026: EPS -$1.06 vs -$0.92 expected — a miss of 15.2%.
Does DYN pay a dividend?
DYN does not currently pay a dividend.
How much debt does DYN have?
Dyne Therapeutics, Inc. reported $200M of debt and $913M of cash (Sep 30, 2026).
What are DYN support and resistance levels?
Support: $17.59, $16.34, $15.31. Resistance: $19.39, $21.71, $24.58.
What are insiders doing with DYN?
Insider activity: NEUTRAL, 5 buys and 14 sells in the last 90 days.
What is the latest news on DYN?
Nov 5, 2026: Dyne Therapeutics Posts Q3 2026 Financials · Nov 5, 2026: Dyne Therapeutics posts wider quarterly loss than analysts expected · Nov 5, 2026: Dyne Therapeutics, Inc. filed a report on a major company event (Form 8-K)